Pulse Biosciences publishes benign thyroid nodules data in Journal Thyroid

Pulse Biosciences (PLSE) announced a new publication in the Journal Thyroid. The First-in-Human Clinical feasibility study demonstrates the effectiveness of ablation of benign thyroid nodules using nsPFA energy. The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the treatment of symptomatic benign thyroid nodules with minimal side effects. The study was conducted by Professor Stefano Spiezia as a single-arm First-In-Human feasibility study at the Ospedale del Mare center in Naples, Italy. The CellFX nsPFA Percutaneous Electrode System was used under ultrasound guidance to ablate benign thyroid nodules, as either isolated ablations to assess tissue response or for full treatment of thyroid nodules with therapeutic intent. Results showed no intranodular fibrosis or scarring on follow-up ultrasounds and fully treated nodules had up to 93% reduction in size at 1 year on ultrasound assessment, with symptom relief and greater than48% reduction as early as 2 weeks.